PARIS, France, Sept. 21 (TNSres) -- Sanofi, a life sciences company, issued the following news release:

* * *

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

* Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescents